Evaluation of the Abbott ARCHITECT Chagas prototype assay

被引：19
|
作者：
Praast, Gerald [1 ]
Herzogenrath, Joerg [1 ]
Bernhardt, Stephanie [1 ]
Christ, Heike [1 ]
Sickinger, Eva [1 ]
机构：
[1] Abbott GmbH & Co KG, D-65205 Wiesbaden, Germany
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2011年 / 69卷 / 01期
关键词：
Chagas disease; Recombinant antigens; Chagas IgG; TRYPANOSOMA-CRUZI ANTIGENS; SEROLOGICAL DIAGNOSIS; RECOMBINANT ANTIGENS; SYNTHETIC PEPTIDE; DISEASE; ANTIBODIES; PROTEIN; TESTS;
D O I：
10.1016/j.diagmicrobio.2010.08.019
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Serologic tests are established tools for the diagnosis of Chagas disease applied to support a safe blood supply in endemic countries. However, sensitivity and specificity of most commercially available enzyme-linked immunosorbent assays (ELISAs) are not regarded as adequate enough to rely on a single assay to determine the Trypanosoma cruzi infection status of a blood donor or a patient. The overall assay performance is driven by the general choice of antigens and the actual antigen cocktail provided in the test. In this report we describe key performance data of the Abbott ARCHITECT Chagas prototype assay in comparison to the well-recognized bioMerieux ELISA cruzi assay. The ARCHITECT assay demonstrated superior specificity (99.99% versus 99.93%) and sensitivity (99.85% versus 98.38%), along with excellent precision, thus showing the potential to serve as single assay to determine the T. cruzi status of a given blood unit or diagnostic specimen on a fully automated instrument platform. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码：74 / 81
页数：8
相关论文
共 50 条
  • [1] EVALUATION OF THE RECOMBINANT ARCHITECT CHAGAS PROTOTYPE ASSAY
    Sickinger, E.
    Herzogenrath, J.
    VOX SANGUINIS, 2010, 99 : 312 - 312
  • [2] Performance evaluation of the prototype ABBOTT chagas confirmatory assay
    Jones, S.
    Becho, J. R.
    Perez, R.
    Kalmin, N. D.
    Shah, D. O.
    Cheng, K.
    Marchlewicz, B.
    TRANSFUSION, 2007, 47 (03) : 208A - 208A
  • [3] Evaluation of the Abbott Architect Cyclosporine Assay
    Maine, G. T.
    Levine, D. M.
    Amann, S. M.
    Parker, T. S.
    Chang, J. S.
    Lorey, T.
    Hoke, C.
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 639 - 639
  • [4] EVALUATION OF THE ABBOTT ARCHITECT CYCLOSPORINE ASSAY
    Levine, D. M.
    Amann, S. M.
    Parker, T. S.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A258 - A259
  • [5] Analytical evaluation of the Abbott ARCHITECT Sirolimus assay
    Maine, G. T.
    Kahn, S. E.
    Vazquez, D.
    Meyer, P.
    Dickson, D.
    Kenney, D.
    Edwards, M.
    Haverstick, D. M.
    CLINICAL BIOCHEMISTRY, 2008, 41 (14-15) : 1277 - 1277
  • [6] Evaluation of the restandardised Abbott Architect oestradiol assay
    Donaldson, A
    Marks, K
    Saunders, L
    Chapman, RS
    CLINICA CHIMICA ACTA, 2005, 355 : S239 - S240
  • [7] Evaluation of the Abbott ARCHITECT Toxo IgM assay
    Sickinger, Eva
    Braun, Hans-Bertram
    Praast, Gerald
    Stieler, Myriam
    Gundlach, Cordelia
    Birkenbach, Claudia
    Prostko, John
    Palafox, Mary Ann
    Frias, Edwin
    Hsu, Stephen
    Matias, Matthew
    Pucci, Dominick
    Hausmann, Michael
    Sagel, Ulrich
    Smith, Darwin
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 64 (03) : 275 - 282
  • [8] Analytical evaluation of the Abbott ARCHITECT sirolimus assay
    Kahn, S. E.
    Vazquez, D.
    Meyer, P.
    Dickson, D.
    Kenney, D.
    Edwards, M.
    Haverstick, M.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A14 - A14
  • [9] Evaluation of Fujirebio Sirolimus assay on the Abbott architect
    Gonsorcik, V.
    Pederson, E. C.
    Castellani, W. J.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A85 - A85
  • [10] EVALUATION OF COPPER ASSAY IN SERUM ON THE ABBOTT ARCHITECT ANALYZER
    Coric, J.
    Panjeta, M.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S753 - S753
12345